

MOL 24463

**POINT MUTATIONS IN EITHER SUBUNIT OF THE GABA_B RECEPTOR CONFER
CONSTITUTIVE ACTIVITY TO THE HETERODIMER**

**Richa S. Mukherjee, Edward W. McBride, Martin Beinborn, Kathleen Dunlap
and Alan S. Kopin**

**Molecular Pharmacology Research Center (R.M., E.M., M.B., A.K.), Molecular
Cardiology Research Institute, Tufts-New England Medical Center, Boston, MA-02111 and
Department of Neuroscience (A.K. , K.D.), Tufts University School of Medicine, Boston,
MA-02111.**

MOL 24463

Running Title: **Constitutively Active GABA_B Receptors**

Correspondence should be addressed to: Dr. Alan S. Kopin, 750 Washington street, P.O. Box
7703, Boston, MA-02111; Tel.: 617-636-4834; Fax: 617-636-8692;

Email: akopin@tufts-nemc.org.

Number of text pages: 35

Number of tables: 2

Number of figures: 7

Number of references: 40

Number of words in Abstract: 249

Number of words in Introduction: 662

Number of words in Discussion: 1755

ABBREVIATIONS: GABA, gamma-amino butyric acid; GABA_BR, GABA_B receptor; GPCR, G-protein coupled receptor; TM, transmembrane domain; R1, GABA_B receptor subunit 1; R2, GABA_B receptor subunit 1; CaSR, Calcium sensing receptor; mGluR1, metabotropic glutamate receptor-subtype 1; VFTM, venus flytrap module; CGP54626, [*S*-(*R**,*R**)]-[3-[[1-(3,4-Dichlorophenyl)ethyl]amino]-2-hydroxypropyl](cyclohexylmethyl)phosphinic acid; CGP52432, 3-[[[(3,4-Dichlorophenyl)methyl]amino]propyl] diethoxymethyl)phosphinic acid; CGP55845, (2*S*)-3-[[[(1*S*)-1-(3,4-Dichlorophenyl)ethyl]amino]-2-hydroxypropyl](phenylmethyl)phosphinic

MOL 24463

acid; CGP 35348, (3-Aminopropyl)(diethoxymethyl)phosphinic acid; Baclofen, R(+)- β -
(Aminomethyl)-4-chlorobenzenepropanoic acid hydrochloride.

MOL 24463

ABSTRACT

The gamma-aminobutyric acid receptor (GABA_BR) is a class C GPCR that functions as an obligate heterodimer, comprised of two heptahelical subunits, R1 and R2. In this study, we generated and pharmacologically characterized constitutively active GABA_BR mutants as novel tools to explore the molecular mechanisms underlying receptor function. A single amino acid substitution, T290K, in the R1 agonist binding domain results in ligand independent signaling when this mutant subunit is coexpressed with wild type R2. Introduction of a Y690V mutation in the putative G protein-coupling domain of R2 is sufficient to confer moderate constitutive activity when this subunit is expressed alone. Activity of the Y690V mutant can be markedly enhanced with coexpression of wild type R1. Coexpression of both mutant subunits (R1-T290K and R2-Y690K) leads to a further increase in basal signaling. Potencies of the full agonists, baclofen and GABA, are increased at the constitutively active vs. the corresponding wild type receptors. The mutant GABA_BR variants provided a sensitive probe enabling detection of inverse or partial agonist activity of molecules previously considered neutral antagonists. Our studies utilizing constitutively active isoforms provide independent support for a model of GABA_BR function which takes into account (i) ligand binding by R1 (ii) signal transduction by R2 and (iii) modulation of R2 induced function by R1. Furthermore, we demonstrate that certain hallmark features of constitutive activity as originally established with class A GPCRs (e.g., enhanced agonist potency and affinity), are more generally applicable, as suggested by our finding with a class C heterodimeric receptor.

MOL 24463

Gamma-aminobutyric acid (GABA) is an inhibitory neurotransmitter that acts through both ionotropic (type A) and metabotropic (type B) receptors. The GABA_A receptor is a chloride channel that is rapidly gated in response to GABA binding. In contrast, the GABA_B receptor (GABA_BR) belongs to the class C family of seven transmembrane domain G-protein coupled receptors (GPCRs), which also includes glutamate, calcium sensing, pheromone, and sweet taste receptors. Most members of the class C family are known to form homodimers. In contrast, the GABA_BR is an obligate heterodimer which is comprised of two homologous subunits, R1 and R2 (Kaupmann et al., 1998; White et al., 1998). Each GABA_BR subunit has a heptahelical domain as well as a large N-terminal region that includes a venus flytrap module (VFTM) (Margeta-Mitrovic et al., 2001). This N-terminal segment shares sequence similarity with certain bacterial periplasmic-binding proteins (O'Hara et al., 1993).

Unlike other class C receptors, the two subunits of the heterodimeric GABA_BR play distinct roles in receptor activation. The VFTM of R1 confers agonist affinity (Pin et al., 2003; Takahashi et al., 1993), whereas R2 triggers G protein (Gi/Go) activation (Duthey et al., 2002; Galvez et al., 2001). R2 also controls intracellular trafficking of R1, thereby enabling R1 to reach the cell surface (Margeta-Mitrovic et al., 2001; Pagano et al., 2001; Robbins et al., 2001). In addition to Gi/Go mediated inhibition of adenylate cyclase, GABA_BR stimulation also leads to effector responses through G protein βγ subunits. Beta-gamma mediated signaling includes activation of GIRK-type potassium channels and inhibition of voltage-gated calcium channels.

The GABA_BR is widely expressed in the peripheral and central nervous systems. Pharmacologic modulation of this GPCR offers a potential treatment option for neurologic disorders including epilepsy, pain, anxiety and spasticity (Bowery et al., 2002; Sanger et al., 2002; Vaught et al., 1985). Baclofen, a GABA_BR agonist, identified prior to the cloning of

MOL 24463

the receptor, has been used to treat spasticity for more than 30 years. Ongoing screening efforts in the pharmaceutical industry using the recombinant GABA_BR are aimed at expanding the range of receptor selective drugs (Marshall, 2005).

Cumulative evidence suggests that agonist stimulation of a GPCR triggers a transition from the inactive to the active receptor state leading to the induction of second messenger signaling (Gether, 2000). Even in the absence of agonist, however, many GPCRs exhibit a limited degree of ligand-independent (constitutive) signaling that is determined by the equilibrium between active and inactive conformations of the receptor (Adan and Kas, 2003). Constitutive activity of a given GPCR can be increased by introduction of receptor point mutations that further favor the active state. The vast majority of constitutively active receptors are “partially on” (i.e. stimulation with agonist leads to a further shift toward the active state and an increase in second messenger signaling).

Stimulation with agonist and induction of mutation-induced ligand-independent signaling offer complementary approaches to probe the mechanisms underlying receptor activation. Although activating point mutations have been described for many GPCRs, none has been reported for heterodimeric receptors, leading to the question of whether there are fundamental differences between homo- and heterodimeric receptors.

In the studies described here, we demonstrate that selected single amino acid substitutions in either GABA_BR subunit result in significant constitutive activity of the heterodimers formed from an association of mutant and complementary wild type subunits. Coexpression of both mutant subunits leads to an even more pronounced increase in basal signaling. In prior studies, it has been observed that ligand independent signaling could be induced by either (i) introduction of a disulfide bridge within the putative ligand binding pocket or (ii) coexpression of a wild type

MOL 24463

and a chimeric R1/R2 subunit (Kniazeff et al., 2004; Galvez et al., 2001). In contrast to these GABA_BR constructs, the constitutively active mutants described in our study show conserved ligand binding and agonist-stimulated function. These features enable further pharmacological analysis of the different constitutively active GABA_BR mutants thereby providing insight into the principles underlying signaling by a class C heterodimeric receptor.

MOL 24463

MATERIALS AND METHODS

Cloning of the mouse R1 and R2 subunits. PCR primers were designed to amplify the open reading frame of each mouse GABA_BR subunit (supplemental *Table 1*). As template for PCR, oligo-dT primed first strand cDNA was generated by reverse transcription of mouse brain mRNA. For PCR amplification, the following parameters were utilized: 30 cycles, each including denaturation at 94°C for 30 sec, annealing at 60°C for 30 sec, and extension at 72°C for 3 min. Following the last cycle, a final extension period of 10 min at 72°C was completed.

Primers (supplemental *Table 1*) were designed to amplify two overlapping segments of cDNA encoding the R1 subunit (GenBank accession no. AF008649). The two resulting PCR products were then ligated using a unique *Bsu36I* site and subcloned into the expression vector pcDNA1.1 (Invitrogen, San Diego).

An analogous strategy was used to amplify the R2 cDNA. In this case, the 5' primer (R2-A1 in supplemental *Table 1*) was designed from the mouse R2 genomic sequence which shares 100% identity with the corresponding 5' end of the rat R2 cDNA (GenBank accession no. AF074482). The 3' primer (R2-B2 in supplemental *Table 1*) was designed based on the untranslated region of the mouse gene. Internal primers (R2-A2 and R2-B1 in supplemental *Table 1*) hybridized to protein coding segments that are conserved between the mouse gene as well as the rat and human cDNAs. Following PCR amplification, two overlapping segments of cDNA, which together encode the complete R2 protein-coding region were ligated using a naturally occurring *BamH1* site and then subcloned into pcDNA1.1.

The nucleotide sequence of the protein-coding region of each receptor cDNA was confirmed using automated DNA sequencing (model 373; Applied Biosystems, Foster City, CA).

MOL 24463

Generation of mutant receptors. R1 and R2 mutations were introduced into the corresponding cDNA using oligonucleotide-directed site-specific mutagenesis as previously described (Beinborn et al., 1993; Blaker et al., 1998). The nucleotide sequence of the protein-coding region of each mutant receptor cDNA was confirmed using automated DNA sequencing.

Luciferase reporter gene assays. Human embryonic kidney (HEK293) cells were plated (5,000–7,000 per well) onto 96-well Primaria plates (BD Biosciences, Bedford, MA). After an overnight incubation, cells were transiently transfected with cDNAs encoding each of the following (unless otherwise noted): R1, R2, G_{q5i} and an SRE_{5x} luciferase reporter gene construct. As previously reported, G_{q5i} enables $G_{i/o}$ coupled receptor activity to be detected using an SRE-luciferase reporter gene (Feuerbach et al., 2000; Hearn et al., 2002). Transfections were done with lipofectamine reagent (Invitrogen) according to the manufacturer's instructions. Twenty-four hours post-transfection, cells were incubated in serum-free Dubecco's modified Eagle's medium (Gibco, Carlsbad, CA) either in the absence (for determination of basal activity) or presence of ligand. After overnight stimulation, cells were lysed and luciferase activity was quantified using the LucLite luminescence reporter gene assay system (PerkinElmer, Boston, MA). GABA_BR ligands that were studied included CGP54626, CGP52432, CGP55845, CGP35348 (Tocris Cookson Ltd, Bristol, United Kingdom) as well as baclofen and GABA (Sigma, St. Louis, MO).

Radioligand binding experiments. Binding assays were performed as previously described (Lee et al., 1993) with minor modifications. COS-7 cells (10⁶/10 cm plate) were transfected using the DEAE dextran method with 5 μg of each relevant GABA_BR subunit cDNA. After ~16

MOL 24463

hours, cells were split into 24-well plates (80,000 cells/ well). The following day, cells were incubated for 80 minutes at room temperature with 20nM ^3H -CGP54626 (Tocris Cookson Ltd, Bristol, United Kingdom) in the presence of increasing concentrations of unlabeled GABA or CGP54626. Non-specific binding was assessed in parallel using cells transfected with the empty expression vector, pcDNA1.1.

Data analysis. Ligand concentration-response and competition curves were analyzed using GraphPad Prism software version 3.0 (GraphPad, San Diego, CA). All analyses were based on at least three independent experiments. Statistical comparisons were made using InStat software version 3.01 (GraphPad) to calculate either analysis of variance (Dunnett's post-tests) or unpaired t-tests (two-tailed P values).

MOL 24463

RESULTS

Cloning and functional assessment of the mouse R1 and R2 subunits. The cloned R1 sequence that we obtained by PCR is in full agreement with the previously reported cDNA (GenBank accession no. AF008649 and AF114168).

In addition to the R1 subunit, we cloned R2 using RT-PCR. Based on computational analysis of the corresponding gene, the mouse R2 cDNA sequence had been predicted to encode a 1455 amino acid protein (Genbank accession no. XM143750). In the current study, we have experimentally established that the actual cDNA encodes a 940 amino acid protein. The discrepancy between the computationally annotated and the cloned mouse R2 cDNA sequence can be attributed to mistaken inclusion of intron segments in the computationally predicted transcript. The cloned mouse R2 cDNA shows a high degree of conservation with other mammalian homologs. The encoded R2 protein is 99.6 % and 98 % identical to the rat and human R2 subunits, respectively (supplemental *Fig. 1*).

As with all known species homologs of this receptor, the mouse GABA_BR functions as a heterodimer comprised of an R1 and an R2 subunit. GABA induced signaling was observed only in cells expressing both GABA_B receptor subunits. In the absence of corresponding heterodimeric partners, basal activity of either the R1 or the R2 subunits approached zero. Of note, as reported for the rat homolog (Grunewald et al., 2002), the wild type mouse GABA_BR shows an appreciable level of constitutive activity (*Fig. 1*).

A single amino acid substitution in either R1 or R2 results in constitutive activity.

Within each class of GPCR (A, B, as well as C), naturally occurring activating mutations have

MOL 24463

been identified and shown to underlie the development of receptor specific disease (Seifert and Wenzel-Seifert, 2002). Hints about promising candidate domains for mutation-induced receptor activation can often be derived by aligning a target receptor with a related GPCR in which naturally occurring constitutively active variants are known. Utilizing this approach, the GABA_B R1 and R2 amino acid sequences were aligned with constitutively active variants of the calcium sensing receptor (known to result in hypocalcemia) (Jensen et al., 2000) to identify candidate domains for mutagenesis. Based on this rationale, we introduced a series of potential activating mutations into both the R1 and R2 subunits (*Table 1*). Analysis of these constructs led to the identification of a residue in R2, Y690, where four different substitutions resulted in enhanced basal signaling (when each R2 mutant was coexpressed with wild type R1, *Table 1*). Among the constitutively active R2 mutants (*Table 1*), the Y690V variant had the highest level of basal signaling and was therefore selected for further study (*Fig. 1, 2*). It is of note that expression of R2 (Y690V) even in the absence of R1 showed a low yet detectable level of constitutive activity (*Fig. 1*). However, like the wild type R2 subunit, R2 (Y690V) in the absence of R1 does not respond to GABA.

Although targeted mutagenesis of R2 was successful in identifying a constitutively active variant, a parallel approach with the R1 subunit did not confer ligand independent signaling (*Table 1*). Further mutagenesis of residues within the R1 VFTM revealed that a T290K substitution resulted in constitutive activity when the mutant was coexpressed with the wild type R2 subunit (*Fig. 1, 2*). Replacement of T290 with Arg, another basic residue also led to an elevation in basal signaling. In contrast, substitution with Leu, a neutral residue, did not induce constitutive activity.

MOL 24463

When the most active isoforms of each GABA_BR subunit, R1 (T290K) and R2 (Y690V), were coexpressed, an even higher level of basal signaling was observed. Of note, despite the marked differences in constitutive activity among the wild type/mutant heterodimer combinations, the maximum level of GABA mediated signaling remained comparable (*Fig. 1*).

GABA and baclofen potency are increased at the constitutively active receptors. To explore the response of the constitutively active R1 and R2 mutants to agonists, HEK293 cells expressing different heterodimer combinations were stimulated with increasing concentrations of GABA or baclofen (*Fig. 3, 4*). When either the R1 (T290K) or the R2 (Y690V) subunit was coexpressed with the complementary wild-type subunit, the mutant heterodimer showed a significantly lower EC₅₀ for GABA versus the wild type value (*Table 2*). Similar potency shifts were observed using baclofen as the agonist. In addition, when both mutants R1 (T290K) and R2 (Y690V) were coexpressed, baclofen potency was further increased. Taken together, our results suggest a trend; increased basal activity is associated with higher agonist potency.

The high affinity putative antagonists CGP54626, CGP52432 and CGP55845 function as inverse agonists at the constitutively active receptors. Several compounds that were previously described as high affinity GABA_BR antagonists were tested for activity on each of the constitutively active mutants (*Fig. 3*). HEK 293 cells expressing combinations of wild type and/or constitutively active GABA_BR mutant subunits were incubated with increasing concentrations of CGP54626, CGP52432 or CGP55845 (*Fig. 5*). Each of these compounds attenuated basal signaling of the constitutively active receptors and was thus classified as an inverse agonist. We found a trend suggesting a reciprocal relationship between constitutive

MOL 24463

receptor activity and potency of each inverse agonist. A statistically significant decrease in potency was found for CGP52432 and CGP55845 when assessed at the double mutant heterodimer, R1 (T290K)/R2 (Y690V) versus the wild-type receptor (*Table 2*).

CGP35348 shows partial agonist activity at the constitutively active GABA_B receptors.

CGP35348 is described in the literature as a low affinity antagonist at the wild type GABA_BR. Using the luciferase reporter gene assay, assessment of this compound at the wild-type GABA_BR revealed trace partial agonist activity. At the constitutively active GABA_BR mutants the efficacy of CGP35348 was more readily detectable (*Fig 6*). As observed with GABA and baclofen, there was a trend toward higher potency of CGP35348 with increasing constitutive receptor activity (*Table 2*). The increase in CGP35348 reached significance when assessed at the double mutant heterodimer, R1 (T290K)/R2 (Y690K).

Ligand binding assays with radiolabeled CGP54626. To evaluate the effect of the activating mutations on ligand affinities, we performed radioligand competition binding assays on COS-7 cells expressing either the wild type GABA_B receptor (R1/R2) or one of three mutant heterodimers, R1/R2 (Y690V), R1 (T290K)/R2 or R1 (T290K)/R2 (Y690V) (*Fig. 7*). The double mutant heterodimer showed a >100-fold increase in GABA affinity when compared with the wild type receptor. Expression of either R1 (T290K) or R2 (Y690V) with the complementary wild type subunit showed a 20- or a 12- fold increase in GABA affinity, respectively, when compared with the wild type heterodimer. Homologous competition binding experiments using radio-labeled versus unlabeled CGP54626, were used to assess the density of binding sites on cells expressing the different GABA_BR constructs. Corresponding values

MOL 24463

(mean \pm S.E.M, n=4) were as follows: wild type GABA_BR (R1/R2), 2.73 ± 0.65 fmol/10³ cells; R1/R2 (Y690V), 2.83 ± 0.63 fmol/10³ cells; R1 (T290K)/R2, 2.56 ± 0.55 fmol/10³ cells and R1 (T290K)/R2 (Y690V), 2.73 ± 0.63 fmol/10³ cells (no significant difference by ANOVA).

MOL 24463

DISCUSSION

The present study led to the novel observation that a single amino acid substitution in either of the two GABA_BR subunits can result in agonist-independent signaling by a heterodimeric GPCR. The availability of these receptor constructs offers the opportunity to investigate agonist versus mutation-induced activation of a class C receptor. The GABA_BR is of additional interest given that this receptor is the prototype obligate heterodimer within the GPCR superfamily (Jones et al., 1998; Kaupmann et al., 1998; Kuner et al., 1999; White et al., 1998) and represents a key target for drug development in the therapeutic areas of human epilepsy, pain, and spasticity.

Much has been learned about GABA_BR function by comparison with the related class C metabotropic glutamate receptor, mGluR1. Crystallographic studies of this homodimeric receptor revealed that the N-terminal extracellular region of each subunit includes a bilobate domain (VFTM) which is homologous to bacterial periplasmic proteins (Kunishima et al., 2000; O'Hara et al., 1993; Tsuchiya et al., 2002). Current evidence from mutagenesis studies suggests that agonist stimulation triggers at least one bilobate domain to close. This appears to result in a conformational change in other parts of the receptor (i.e., the helical domain), which in turn activates G-proteins. The role of the VFTM, as first described for the mGluR1, is thought to be conserved in other class C GPCRs including the GABA_BR.

We observed that a mutation in the GABA_BR1 VFTM (T290K) resulted in constitutive activity that was appreciable only when this subunit was coexpressed with wild-type R2. This may indicate that the N-terminal residue substitution in R1 induces a conformational change similar to that induced by GABA binding, and thus results in activation of second messenger

MOL 24463

signaling through R2. Since R2 does not bind GABA, it would be anticipated based on current models, that a homologous mutation in the VFTM of the R2 subunit would not trigger constitutive activity. Consistent with this expectation, the corresponding mutation within the R2 subunit (N179K) did not induce ligand-independent signaling (see supplemental *Fig.2*).

Much has been learned about the ligand binding mechanism of class C receptors by comparison with the metabotropic glutamate receptor. The crystal structure of the glutamate-bound form of mGluR1 revealed key residues at the interface of the two lobes of the VFTM that are involved in glutamate binding (Kunishima et al., 2000; O'Hara et al., 1993; Tsuchiya et al., 2002). Current evidence suggests that agonist stimulation of mGlu1R triggers VFTM closure. Among the residues that comprise the glutamate binding pocket is D208. Homology modeling suggests that the corresponding residue in the mouse GABA_B R1 is A291 (Kniazeff et al., 2002). In our study, we demonstrate that mutation of the adjacent R1 amino acid, T290K, results in ligand independent signaling. We speculate that the positively charged lysine introduced in place of T290 interacts with one or more negatively charged residue(s) within or proximal to the putative ligand pocket, thereby inducing closure of the venus fly trap. This proposed mechanism is reminiscent of the previously reported constitutive receptor activation resulting from closure of the VFTM due to introduction of a disulfide bridge in this domain (Kniazeff et al., 2004). In contrast to the constitutively active mutants described in the current study which maintain agonist responsiveness, covalent modification of the receptor abolished ligand induced function.

Mutation of the R2 subunit, Y690V also resulted in constitutive activity. The Y690V substitution is located at the transition between transmembrane domain VI and the third intracellular loop, a putative G protein binding domain (Duthey et al., 2002). The location of this activating substitution raises the possibility that constitutive activity results from a mutation

MOL 24463

induced change in the interaction between GABA_BR and the G-protein. In addition, our findings provide independent support for the postulated mechanism of GABA_BR mediated signaling, in which G protein coupling occurs through the R2 subunit (Duthey et al., 2002; Havlickova et al., 2002; Robbins et al., 2001). Consistent with this model, the homologous mutation in R1 (A803V) does not induce ligand independent signaling (see supplemental *Fig. 2*).

In contrast to R1 (T290K) (which exhibits no activity in the absence of R2), the R2 variant, Y690V, shows a low level of constitutive activity even when expressed alone. This observation is in accordance with the established ability of R2 to independently reach the cell surface and confer G protein coupling (Binet et al., 2004; Pin et al., 2004). Our finding that constitutive activity of R2 (Y690V) is greatly enhanced with coexpression of wild type R1 suggests that the latter subunit acts as a positive modulator of R2-mediated signaling, in addition to its well-established role as a GABA binding site. In fact, our observation provides independent support for the postulated role of R1 as an enhancer of R2 coupling efficiency. The concept that R1 acts as a modulator of R2 function was originally proposed to explain unexpected pharmacological properties of chimeric GABA_B R heterodimers. These constructs were engineered to include only one type (either R1 or R2) of helical domain (Galvez et al., 2001; Knaizeff et al., 2004; Pin et al., 2004). Study of these chimeric receptors demonstrated that absence of the R1 helical domain markedly reduced the efficacy and potency of GABA (Galvez et al., 2001). These findings, together with our observation that constitutive activity of a variant R2 is markedly enhanced by R1, suggest that GABA_BR signaling, in the presence or absence of ligand is enabled by an interplay between the helical domains of both subunits.

In addition to the point mutations reported in this study, two other GABA_BR modifications have been shown to result in ligand-independent signaling. In one report, it was demonstrated

MOL 24463

that chimeric GABA_BR heterodimers, which include only one type of extracellular domain (either R1 or R2) show a modest degree of basal signaling. Such receptors, however, no longer respond to GABA (Galvez et al., 2001; Pin et al., 2004). A second report describes a constitutively active GABA_BR heterodimer that resulted from introduction of two cysteine residues within the VFTM of R1 (Kniazeff et al., 2004). These residues form a putative disulphide bridge, thus locking the binding domain in a closed position and triggering downstream signaling. Supporting this interpretation, constitutive activity can be inhibited by the reducing agent, DTT.

As opposed to the construct described above, constitutive activity of the mutant receptors, R1 (T290K) and R2 (Y690V), as reported here, does not require covalent modification of either GABA_BR subunit. In the latter variants, the single amino acid substitutions that induce constitutive activity appear to conserve the receptor's ability to undergo transitions between 'active' and 'inactive' states. In contrast to the properties of the previously reported chimeras and cysteine-substituted mutants, ligand binding and agonist-induced function of the R1 (T290K) and R2 (Y690V) receptors remain intact, enabling further studies of the pharmacological changes associated with enhanced basal receptor function.

The current view of GPCR activation suggests that either mutations or agonists can preferentially stabilize the active conformation of a receptor over the inactive state (Samama et al., 1993), thus triggering G protein activation. Conversely, an inverse agonist stabilizes the inactive form of the receptor, thereby decreasing basal receptor signaling. This model was originally proposed based on studies with a constitutively active β -adrenoceptor mutant (Leff, 1995; Samama et al., 1993); its applicability to many other class A GPCRs has subsequently been shown. Collectively, these experiments have revealed certain characteristic features of

MOL 24463

constitutively active receptors that support the model and, at the same time, provide a basis for comparison with structurally distinct receptors (i.e., class C heterodimers).

Constitutively active class A receptors, when compared with corresponding wild type receptor proteins (i) show an increase in agonist potency and affinity (ii) distinguish inverse agonists from antagonists and (iii) have conserved antagonist affinity (Beinborn et al., 1998; Samama et al., 1993; Tiberi and Caron, 1994). Our results suggest that these features can be extrapolated to class C GABA_B receptors, despite their minimal sequence homology with class A receptors and their dependence on heterodimerization as a prerequisite of function. Consistent with the current model of GPCR activation (Kenakin, 2002; Lefkowitz et al., 1993), activating mutations in the GABA_BR that increase basal signaling also enhance agonist potency and affinity (*Figs. 4 and 7; Table 2*). These pharmacologic alterations were observed with point mutations in either GABA_BR subunit when coexpressed with the complementary wild type subunit. In addition, coexpression of the two constitutively active subunits resulted in even more pronounced shifts when compared to the wild type heterodimer.

Another pharmacologic feature which broadly applies to constitutively active receptors is the ability to inhibit ligand-independent signaling with inverse agonists (Beinborn et al., 1998; Samama et al., 1993; Tiberi and Caron, 1994). In the current study, we found that two structurally related compounds, CGP52432 and CGP55845, previously considered as neutral antagonists, inhibited basal signaling of the mutant GABA_BR and should, thus, be classified as inverse agonists. In addition, using GABA_BR mutants with significant basal activity, we were able to confirm the classification of CGP54626 as an inverse agonist. A previous report suggested that CGP54626 had inverse agonist activity when assessed at the rat wild type GABA_BR (like the wild type mouse receptor, the rat homolog shows an appreciable level of

MOL 24463

ligand independent signaling) (Grunewald et al., 2002). All three compounds (CGP54626, CGP52432 and CGP55845) share relatively high GABA_BR binding affinity. It is of note that the potency of the three inverse agonists tends to decrease as the level of constitutive activity increases (i.e as a shift occurs from the inactive to active receptor state). This is consistent with current models in which the ‘inactive’ conformation is most favorable to inverse agonist interactions, whereas agonists preferentially bind the ‘active’ form of the receptor (Gether, 2000).

Constitutively active mutants may be used to detect ligand activity that is not evident at the wild type receptor (*Fig.6*). Once a ligand with intrinsic activity (i.e., an agonist or inverse agonist) is identified, it may be anticipated that structural modification can lead to the identification of full agonists. In an earlier manuscript, our group illustrated this strategy with the CCK-B receptor, a class A GPCR. Reminiscent of our current findings with the GABA_BR, we showed that putative “antagonists” of the wild-type CCK receptor actually had significant partial or inverse agonist activity when tested on a constitutively active CCK-B receptor mutant. Screening of a series of structural derivatives of these compounds led to the identification of molecules with near full agonist activity, both *in vitro* and *in vivo* (Kopin et al., 2003). Based on these prior observations, it will be of interest to examine the activity of structural derivatives of the partial/inverse agonists identified using the constitutively active GABA_B receptors. This approach provides a potential means to expedite the identification of novel, therapeutically useful GABA_BR drugs.

MOL 24463

ACKNOWLEDGEMENTS

We thank Dr. Yong Ren (current address: Synaptic Pharmaceutical Corporation, Paramus, NJ) for discussions during the course of this study.

MOL 24463

REFERENCES

- Adan RA and Kas MJ (2003) Inverse agonism gains weight. *Trends Pharmacol Sci* **24**(6):315-321.
- Beinborn M, Lee YM, McBride EW, Quinn SM and Kopin AS (1993) A single amino acid of the cholecystokinin-B/gastrin receptor determines specificity for non-peptide antagonists. *Nature* **362**(6418):348-350.
- Beinborn M, Quinn SM and Kopin AS (1998) Minor modifications of a cholecystokinin-B/gastrin receptor non-peptide antagonist confer a broad spectrum of functional properties. *J Biol Chem* **273**(23):14146-14151.
- Binet V, Brajon C, Le Corre L, Acher F, Pin JP and Prezeau L (2004) The heptahelical domain of GABA(B2) is activated directly by CGP7930, a positive allosteric modulator of the GABA(B) receptor. *J Biol Chem* **279**(28):29085-29091.
- Blaker M, Ren Y, Gordon MC, Hsu JE, Beinborn M and Kopin AS (1998) Mutations within the cholecystokinin-B/gastrin receptor ligand 'pocket' interconvert the functions of nonpeptide agonists and antagonists. *Mol Pharmacol* **54**(5):857-863.
- Bowery NG, Bettler B, Froestl W, Gallagher JP, Marshall F, Raiteri M, Bonner TI and Enna SJ (2002) International Union of Pharmacology. XXXIII. Mammalian gamma-aminobutyric acid(B) receptors: structure and function. *Pharmacol Rev* **54**(2):247-264.
- Duthey B, Caudron S, Perroy J, Bettler B, Fagni L, Pin JP and Prezeau L (2002) A single subunit (GB2) is required for G-protein activation by the heterodimeric GABA(B) receptor. *J Biol Chem* **277**(5):3236-3241.

MOL 24463

Feuerbach D, Fehlmann D, Nunn C, Siehler S, Langenegger D, Bouhelal R, Seuwen K and

Hoyer D (2000) Cloning, expression and pharmacological characterisation of the mouse somatostatin sst(5) receptor. *Neuropharmacology* **39**(8):1451-1462.

Galvez T, Duthey B, Kniazeff J, Blahos J, Rovelli G, Bettler B, Prezeau L and Pin JP (2001)

Allosteric interactions between GB1 and GB2 subunits are required for optimal GABA(B) receptor function. *Embo J* **20**(9):2152-2159.

Gether U (2000) Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. *Endocr Rev* **21**(1):90-113.

Grunewald S, Schupp BJ, Ikeda SR, Kuner R, Steigerwald F, Kornau HC and Kohr G (2002)

Importance of the gamma-aminobutyric acid(B) receptor C-termini for G-protein coupling. *Mol Pharmacol* **61**(5):1070-1080.

Havlickova M, Prezeau L, Duthey B, Bettler B, Pin JP and Blahos J (2002) The intracellular

loops of the GB2 subunit are crucial for G-protein coupling of the heteromeric gamma-aminobutyrate B receptor. *Mol Pharmacol* **62**(2):343-350.

Hearn MG, Ren Y, McBride EW, Reveillaud I, Beinborn M and Kopin AS (2002) A Drosophila dopamine 2-like receptor: Molecular characterization and identification of multiple alternatively spliced variants. *Proc Natl Acad Sci U S A* **99**(22):14554-14559.

Jensen AA, Spalding TA, Burstein ES, Sheppard PO, O'Hara PJ, Brann MR, Krogsgaard-Larsen P and Brauner-Osborne H (2000) Functional importance of the Ala(116)-Pro(136) region in the calcium-sensing receptor. Constitutive activity and inverse agonism in a family C G-protein-coupled receptor. *J Biol Chem* **275**(38):29547-29555.

Jones KA, Borowsky B, Tamm JA, Craig DA, Durkin MM, Dai M, Yao WJ, Johnson M,

Gunwaldsen C, Huang LY, Tang C, Shen Q, Salon JA, Morse K, Laz T, Smith KE,

MOL 24463

- Nagarathnam D, Noble SA, Branchek TA and Gerald C (1998) GABA(B) receptors function as a heteromeric assembly of the subunits GABA(B)R1 and GABA(B)R2. *Nature* **396**(6712):674-679.
- Kaupmann K, Malitschek B, Schuler V, Heid J, Froestl W, Beck P, Mosbacher J, Bischoff S, Kulik A, Shigemoto R, Karschin A and Bettler B (1998) GABA(B)-receptor subtypes assemble into functional heteromeric complexes. *Nature* **396**(6712):683-687.
- Kenakin T (2002) Drug efficacy at G protein-coupled receptors. *Annu Rev Pharmacol Toxicol* **42**:349-379.
- Kniazeff J, Galvez T, Labesse G and Pin JP (2002) No ligand binding in the GB2 subunit of the GABA(B) receptor is required for activation and allosteric interaction between the subunits. *J Neurosci* **22**(17):7352-61.
- Kniazeff J, Saintot PP, Goudet C, Liu J, Charnet A, Guillon G and Pin JP (2004) Locking the dimeric GABA(B) G-protein-coupled receptor in its active state. *J Neurosci* **24**(2):370-377.
- Kopin AS, McBride EW, Chen C, Freidinger RM, Chen D, Zhao CM and Beinborn M (2003) Identification of a series of CCK-2 receptor nonpeptide agonists: sensitivity to stereochemistry and a receptor point mutation. *Proc Natl Acad Sci U S A* **100**(9):5525-5530.
- Kuner R, Kohr G, Grunewald S, Eisenhardt G, Bach A and Kornau HC (1999) Role of heteromer formation in GABA(B) receptor function. *Science* **283**(5398):74-77.
- Kunishima N, Shimada Y, Tsuji Y, Sato T, Yamamoto M, Kumasaka T, Nakanishi S, Jingami H and Morikawa K (2000) Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. *Nature* **407**(6807):971-977.

MOL 24463

- Lee YM, Beinborn M, McBride EW, Lu M, Kolakowski LF, Jr. and Kopin AS (1993) The human brain cholecystokinin-B/gastrin receptor. Cloning and characterization. *J Biol Chem* **268**(11):8164-8169.
- Leff P (1995) The two-state model of receptor activation. *Trends Pharmacol Sci* **16**(3):89-97.
- Lefkowitz RJ, Cotecchia S, Samama P and Costa T (1993) Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. *Trends Pharmacol Sci* **14**(8):303-307.
- Margeta-Mitrovic M, Jan YN and Jan LY (2001) Ligand-induced signal transduction within heterodimeric GABA(B) receptor. *Proc Natl Acad Sci U S A* **98**(25):14643-14648.
- Marshall FH (2005) Is the GABA B heterodimer a good drug target? *J Mol Neurosci* **26**(2-3):169-176.
- O'Hara PJ, Sheppard PO, Thogersen H, Venezia D, Haldeman BA, McGrane V, Houamed KM, Thomsen C, Gilbert TL and Mulvihill ER (1993) The ligand-binding domain in metabotropic glutamate receptors is related to bacterial periplasmic binding proteins. *Neuron* **11**(1):41-52.
- Pagano A, Rovelli G, Mosbacher J, Lohmann T, Duthey B, Stauffer D, Ristig D, Schuler V, Meigel I, Lampert C, Stein T, Prezeau L, Blahos J, Pin J, Froestl W, Kuhn R, Heid J, Kaupmann K and Bettler B (2001) C-terminal interaction is essential for surface trafficking but not for heteromeric assembly of GABA(b) receptors. *J Neurosci* **21**(4):1189-1202.
- Pin JP, Galvez T and Prezeau L (2003) Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors. *Pharmacol Ther* **98**(3):325-354.

MOL 24463

- Pin JP, Kniazeff J, Binet V, Liu J, Maurel D, Galvez T, Duthey B, Havlickova M, Blahos J, Prezeau L and Rondard P (2004) Activation mechanism of the heterodimeric GABA(B) receptor. *Biochem Pharmacol* **68**(8):1565-1572.
- Robbins MJ, Calver AR, Filippov AK, Hirst WD, Russell RB, Wood MD, Nasir S, Couve A, Brown DA, Moss SJ and Pangalos MN (2001) GABA(B2) is essential for g-protein coupling of the GABA(B) receptor heterodimer. *J Neurosci* **21**(20):8043-8052.
- Samama P, Cotecchia S, Costa T and Lefkowitz RJ (1993) A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. *J Biol Chem* **268**(7):4625-4636.
- Sanger GJ, Munonyara ML, Dass N, Prosser H, Pangalos MN and Parsons ME (2002) GABA(B) receptor function in the ileum and urinary bladder of wildtype and GABA(B1) subunit null mice. *Auton Autacoid Pharmacol* **22**(3):147-154.
- Seifert R and Wenzel-Seifert K (2002) Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. *Naunyn Schmiedebergs Arch Pharmacol* **366**(5):381-416.
- Takahashi K, Tsuchida K, Tanabe Y, Masu M and Nakanishi S (1993) Role of the large extracellular domain of metabotropic glutamate receptors in agonist selectivity determination. *J Biol Chem* **268**(26):19341-19345.
- Tiberi M and Caron MG (1994) High agonist-independent activity is a distinguishing feature of the dopamine D1B receptor subtype. *J Biol Chem* **269**(45):27925-27931.
- Tsuchiya D, Kunishima N, Kamiya N, Jingami H and Morikawa K (2002) Structural views of the ligand-binding cores of a metabotropic glutamate receptor complexed with an antagonist and both glutamate and Gd³⁺. *Proc Natl Acad Sci U S A* **99**(5):2660-2665.

MOL 24463

Vaught JL, Pelley K, Costa LG, Setler P and Enna SJ (1985) A comparison of the
antinociceptive responses to the GABA-receptor agonists THIP and baclofen.

Neuropharmacology **24**(3):211-216.

White JH, Wise A, Main MJ, Green A, Fraser NJ, Disney GH, Barnes AA, Emson P, Foord SM
and Marshall FH (1998) Heterodimerization is required for the formation of a functional
GABA(B) receptor. *Nature* **396**(6712):679-682.

MOL 24463

FOOTNOTES

This work was supported by National Institutes of Health grants, 5R01-DK063344, Digestive Disease Research Center Grant P30-DK34928 (GRASP Center) and T32HL069770 (R.M).

Send reprint requests to: Dr. Alan S. Kopin, 750 Washington street, P.O. Box 7703, Boston, MA-02111; Tel.: 617-636-4834; Fax: 617-636-8692; Email: akopin@tufts-nemc.org.

MOL 24463

FIGURE LEGENDS

Fig. 1. Single amino acid substitutions in GABA_BR confer ligand-independent signaling.

HEK293 cells were co-transfected with cDNAs encoding (i) one or both GABA_BR subunits (ii) G_{q5i} and (iii) an SRE_{5x}-luciferase construct. After overnight stimulation in the absence (open bars) or presence (solid bars) of GABA (10⁻⁴ M), luciferase activity was quantified. Data represent the mean ± SEM from at least three independent experiments, each performed in triplicate. Basal values were examined for significance relative to that of the wild type heterodimer (R1+R2) using ANOVA followed by Dunnett's post-test (*, p<0.05 and **, p<0.01). Agonist-stimulated values were compared to the corresponding basal values for a given receptor by unpaired t-test (+, p<0.05 and ++, p<0.001). Abbreviations: pcDNA1.1, empty expression vector; R1, GABA_BR subunit 1; R2, GABA_BR subunit 2.

Fig. 2. Cartoon of the GABA_BR illustrating the domains where activating mutations are localized. Filled black circles represent (i) the T290K substitution in the VFTM of R1 and (ii) the Y690V mutation in the transition region between transmembrane domain VI and the third intracellular loop of R2. Abbreviations: R1, GABA_BR subunit 1; R2, GABA_BR subunit 2; VFTM, venus flytrap module. This figure is reproduced with the permission of Sigma-Aldrich (St. Louis, MO, USA).

Fig. 3. Structural comparison of the compounds used in this study.

MOL 24463

Fig. 4. Constitutively active mutants show higher potency for GABA and baclofen than the corresponding wild type receptor.

Luciferase activity was assessed in HEK293 cells expressing different GABA_B receptor heterodimers, comprised of wild type or mutant subunits as indicated (for methodologic details, see *Fig. 1* legend). After overnight stimulation with increasing concentrations of GABA or baclofen, luciferase activity was quantified and expressed as a percentage of the maximum GABA-induced effect (after stimulation with 10⁻⁴ M GABA). Data represent the mean ± SEM from at least four independent experiments, each performed in triplicate (corresponding EC50 values are listed in *Table 2*). ‘Basal’ indicates the absence of ligand. Abbreviations: R1, GABA_BR subunit 1; R2, GABA_BR subunit 2.

Fig. 5. Putative high affinity antagonists, CGP52432, CGP54626, and CGP55845 function as inverse agonists at each of the constitutively active receptors.

Luciferase activity was assessed in HEK293 cells expressing different GABA_B receptor heterodimers, comprised of wild type or mutant subunits as indicated (for methodologic details, see *Fig. 1* legend). After overnight stimulation with increasing concentrations of CGP54626, CGP52432 or CGP55845, luciferase activity was quantified and expressed as a percentage of the maximum GABA-induced effect (after stimulation with 10⁻⁴ M GABA). Data represent the mean ± SEM from at least three independent experiments, each performed in triplicate (corresponding EC50 values are listed in *Table 2*). ‘Basal’ indicates signaling in the absence of ligand. Abbreviations: R1, GABA_BR subunit 1; R2, GABA_BR subunit 2.

Fig. 6. CGP35348, a putative low affinity antagonist, shows weak partial agonist activity.

Luciferase activity was assessed in HEK293 cells expressing different GABA_B receptor

MOL 24463

heterodimers, comprised of wild type or mutant subunits as indicated (for methodologic details, see *Fig. 1 legend*). After overnight stimulation with increasing concentrations of CGP35348, luciferase activity was quantified and expressed as a percentage of the maximum GABA-induced effect (after stimulation with 10^{-4} M GABA). Data represent the mean \pm SEM from at least three independent experiments, each performed in triplicate (corresponding EC50 values are listed in *Table 2*). ‘Basal’ indicates absence of ligand. Abbreviations: R1, GABA_BR subunit 1; R2, GABA_BR subunit 2.

Fig. 7. Constitutively active GABA_BR mutants show higher affinity for GABA than the wild type heterodimer. COS-7 cells were co-transfected with different GABA_B receptor heterodimers, comprised of wild type or mutant subunits as indicated. Cells were incubated with ³H-CGP54626 in the presence of increasing concentrations of unlabeled competitor, GABA. Mean IC50 values were as follows: R1 + R2, 97700 nM; R1 (T290K) + R2, 5010 nM; R1 + R2 (Y690V), 7940 nM; and R1 (T290K) + R2 (Y690V), 695 nM. Abbreviations: R1, GABA_BR subunit 1; R2, GABA_BR subunit 2.

MOL 24463

Table 1: Mutations introduced into the GABA_BR subunits that correspond to constitutively active CaSR variants. Targeted residues in the R1 and R2 subunits were selected by alignment with the human CaSR.

Substitution in R1	Known CaSR activating mutation	Receptor domain	Constitutive activity^b (GABA_BR)
E165K	E191K	N terminal	No
<u>L</u> WLL 666 <u>H</u> PAF ^a	Q681H	TM3	no
L769R	L773R	TM5	no
<u>A</u> V 804 <u>S</u> ITF ^a	F806S	TM6	no
A803S	F806S	TM6	no
Substitution in R2			
IWL <u>G</u> I 656 M <u>A</u> R <u>G</u> F ^a	L773R	TM5	no
L656R	L773R	TM5	no
Y690V	F806S	TM6	yes
Y690C	F806S	TM6	yes
Y690A	F806S	TM6	yes
Y690G	F806S	TM6	yes
Y690S	F806S	TM6	no
Y690Q	F806S	TM6	no
Y690E	F806S	TM6	no
Y690N	F806S	TM6	no

MOL 24463

Y690W	F806S	TM6	no
Y690K	F806S	TM6	no

^a A block of amino acids in R1 or R2 that were substituted with corresponding amino acids from the CaSR. The corresponding single amino acid activating mutation within the CaSR sequence is underlined.

^b Mutants were assessed for constitutive activity in combination with the complementary GABA_BR wild type subunit.

Table 2: Ligand potencies at the wild type and mutant GABA_B receptors.

Ligand	R1 + R2		R1 (T290K) + R2			R1 + R2 (Y690V)			R1 (290K) + R2 (Y690V)		
	EC50 ^a	pEC50±SEM	EC50 ^a	pEC50±SEM	Shift ^b	EC50 ^a	pEC50±SEM	Shift ^b	EC50 ^a	pEC50±SEM	Shift ^b
GABA	1960	5.71 ± 0.01	665	6.18 ± 0.10 ^d	2.9	600	6.22 ± 0.10 ^d	3.2	723	6.14 ± 0.15 ^c	2.7
Baclofen	2230	5.65 ± 0.06	1047	5.98 ± 0.10	2.1	596	6.22 ± 0.17	3.7	90.6	7.04 ± 0.59 ^c	25
CGP54626	4.9	8.31 ± 0.23	3.4	8.46 ± 0.15	1.4	4.5	8.35 ± 0.15	1.1	20.9	7.68 ± 0.08	0.2
CGP52432	38.0	7.42 ± 0.14	36.9	7.43 ± 0.15	1.0	78.9	7.10 ± 0.10	0.5	419.8	6.37 ± 0.12 ^d	0.1
CGP55845	1.7	8.78 ± 0.29	3.7	8.43 ± 0.08	0.4	8.0	8.09 ± 0.22	0.2	27.4	7.56 ± 0.13 ^d	0.1
CGP35348	14490	4.84 ± 0.21	17180	4.76 ± 0.21	0.8	5320	5.27 ± 0.14	2.8	912	6.04 ± 0.40 ^c	16.7

^a half maximal effective concentration, nM, average of at least three independent experiments.

^b fold shift in EC50, calculated as ratio of EC50 (wild type)/EC50 (mutant).

^c P<0.05 versus WT value.

^d P<0.01 versus WT value.

Fig. 1




Fig. 2







Fig. 3




Gamma-aminobutyric acid (GABA)
(agonist)




Baclofen
(agonist)




CGP35348
(partial agonist)



CGP54626
(inverse agonist)



CGP52432
(inverse agonist)



CGP55845
(inverse agonist)

Fig. 4





Fig. 5






Fig. 6




Fig. 7

